Autori: Brolatti N

Filtra

Data

Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study

Early treatment of type II SMA slows rate of progression of scoliosis

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na‹ve patients with spinal muscular atrophy and following switch from other therapies

Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function

Long term follow-up of scoliosis progression in type II SMA patients

Body mass index in type 2 spinal muscular atrophy: a longitudinal study

Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy

Torna in alto